JP2023506225A5 - - Google Patents

Info

Publication number
JP2023506225A5
JP2023506225A5 JP2022535961A JP2022535961A JP2023506225A5 JP 2023506225 A5 JP2023506225 A5 JP 2023506225A5 JP 2022535961 A JP2022535961 A JP 2022535961A JP 2022535961 A JP2022535961 A JP 2022535961A JP 2023506225 A5 JP2023506225 A5 JP 2023506225A5
Authority
JP
Japan
Prior art keywords
composition according
tasimerteon
mannitol
suspension
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022535961A
Other languages
English (en)
Japanese (ja)
Other versions
JP7503632B2 (ja
JP2023506225A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064555 external-priority patent/WO2021119456A1/en
Publication of JP2023506225A publication Critical patent/JP2023506225A/ja
Publication of JP2023506225A5 publication Critical patent/JP2023506225A5/ja
Priority to JP2024064780A priority Critical patent/JP7875899B2/ja
Application granted granted Critical
Publication of JP7503632B2 publication Critical patent/JP7503632B2/ja
Priority to JP2026061286A priority patent/JP2026117039A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022535961A 2019-12-13 2020-12-11 液体タシメルテオン製剤及びそれを使用する方法 Active JP7503632B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024064780A JP7875899B2 (ja) 2019-12-13 2024-04-12 液体タシメルテオン製剤及びそれを使用する方法
JP2026061286A JP2026117039A (ja) 2019-12-13 2026-04-02 液体タシメルテオン製剤及びそれを使用する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962947774P 2019-12-13 2019-12-13
US62/947,774 2019-12-13
US202062972902P 2020-02-11 2020-02-11
US62/972,902 2020-02-11
US202063119488P 2020-11-30 2020-11-30
US63/119,488 2020-11-30
PCT/US2020/064555 WO2021119456A1 (en) 2019-12-13 2020-12-11 Liquid tasimelteon formulations and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024064780A Division JP7875899B2 (ja) 2019-12-13 2024-04-12 液体タシメルテオン製剤及びそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2023506225A JP2023506225A (ja) 2023-02-15
JP2023506225A5 true JP2023506225A5 (enExample) 2023-12-20
JP7503632B2 JP7503632B2 (ja) 2024-06-20

Family

ID=73856392

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022535961A Active JP7503632B2 (ja) 2019-12-13 2020-12-11 液体タシメルテオン製剤及びそれを使用する方法
JP2024064780A Active JP7875899B2 (ja) 2019-12-13 2024-04-12 液体タシメルテオン製剤及びそれを使用する方法
JP2026061286A Pending JP2026117039A (ja) 2019-12-13 2026-04-02 液体タシメルテオン製剤及びそれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024064780A Active JP7875899B2 (ja) 2019-12-13 2024-04-12 液体タシメルテオン製剤及びそれを使用する方法
JP2026061286A Pending JP2026117039A (ja) 2019-12-13 2026-04-02 液体タシメルテオン製剤及びそれを使用する方法

Country Status (14)

Country Link
US (5) US11202770B2 (enExample)
EP (1) EP4072542A1 (enExample)
JP (3) JP7503632B2 (enExample)
KR (1) KR102650321B1 (enExample)
CN (1) CN114727978A (enExample)
AU (3) AU2020400065B2 (enExample)
CA (1) CA3161975A1 (enExample)
CL (1) CL2022001546A1 (enExample)
CO (1) CO2022009691A2 (enExample)
IL (2) IL292492A (enExample)
MX (2) MX2022006577A (enExample)
NZ (1) NZ811397A (enExample)
WO (1) WO2021119456A1 (enExample)
ZA (1) ZA202207188B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof
AU2022345260A1 (en) 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients
WO2024258786A1 (en) 2023-06-12 2024-12-19 Vanda Pharmaceuticals Inc. Tasimelteon for use in the treatment of delayed sleep-wake phase disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499106B1 (ko) * 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
WO2011112167A1 (en) * 2009-03-13 2011-09-15 Reset Therapeutics, Inc. Compositions and methods for diabetes treatment
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
CN102675268A (zh) 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
IL266159B2 (en) 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6921534B2 (ja) 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
CN106542973B (zh) * 2015-09-16 2019-06-25 南京华威医药科技集团有限公司 他司美琼中间体及其制备方法
WO2017059877A1 (en) 2015-10-07 2017-04-13 Rontis Hellas S.A. Pharmaceutical composition containing agomelatine and process for the preparation thereof
US9944616B2 (en) * 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Similar Documents

Publication Publication Date Title
US7101572B2 (en) Taste masked aqueous liquid pharmaceutical composition
CA2567075C (en) Pharmaceutical suspension composition
RU2241460C2 (ru) Фармацевтическая композиция цефуроксим аксетила с маскированным горьким вкусом
TWI635875B (zh) 包含左旋西替利及蒙特魯卡斯特之具有經改良的穩定性之錯合物顆粒調配物
PT97369B (pt) Processo para a preparacao de formulacoes farmaceutica na qual o sabor do medicamento e disfarcado por meio de revestimento do medicamento com uma membrana polimerica
EA024084B1 (ru) Вводимые перорально кортикостероидные композиции
PT1998762E (pt) Forma farmacêutica sólida contendo um agente activo de sabor mascarado
WO2013175511A1 (en) Taste masked pharmaceutical compositions
ES2641889T3 (es) Formulaciones de diclofenaco y métodos de uso
JP7503632B2 (ja) 液体タシメルテオン製剤及びそれを使用する方法
EP2741750A1 (en) Pharmaceutical composition comprising cefuroxime
JP2711759B2 (ja) 止瀉剤組成物
US9717684B2 (en) Stable montelukast solution
ES2764462T3 (es) Comprimidos de composición farmacéutica oral de uso dual de sales de sulfato y métodos de uso de los mismos
ES2248802T3 (es) Procedimiento para producir preparaciones de flavanolignanos.
EP2005945A2 (en) Oseltamivir phosphate granule and preparation mehtod thereof
JP2010535196A (ja) 活性成分のコーティング膜が保護される口腔内崩壊剤形を製造するための組成物
JP2002332229A (ja) 感冒用組成物
NZ542218A (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid
JP2007131561A (ja) 経口固形製剤及びその製造法
CN116098864B (zh) 一种利那洛肽干混悬剂及其制备方法
CN102048677B (zh) 一种盐酸缬更昔洛韦固体制剂及其制备方法
WO2022074630A1 (en) Liquid oral suspension of favipiravir
JP7239604B2 (ja) 甲状腺ホルモンを含む吸入用の薬学的乾燥粉末組成物
CN101744820A (zh) 包含氢溴酸右美沙芬的药物组合物